Treatment with nabiximols in patients with multiple sclerosis (MS) demonstrated a significant, sustained effect on spasticity numeric rating scale (NRS) score and spasm frequency, regardless of the use of the use of concomitant antispasticity medications (ASMs), such as baclofen. These study findings were presented at the 2022 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) held from June 1-4, in National Harbor, Maryland.
Being told you're delusional does not necessarily mean you're mental.
